Blood Cancer Journal – Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
Friday, December 6, 2024, San Diego, California, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET) Program Schedule — Pacific Time 2:45…
Stereotactic body radiotherapy (SBRT) is increasingly used to treat early-stage non-small cell lung cancer (NSCLC) in medically inoperable patients. Excellent rates of local control (87 %-95 %)…
The use of artificial intelligence (AI) was a central theme at the 2024 ASCO Annual Meeting, including many tools, such as large language models, clinical…
Vivek Subbiah, MD, of Sarah Cannon Research Institute, explains what areas need to be addressed to make precision oncology more accessible.
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer / cancer, dMMR/MSI-H Rectal Cancer, Dostarlimab, FDA, OncoDaily, Oncology,
Jean-Charles Soria: How FcγR engagement influences antibody efficacy, toxicity and pharmacokinetics / Alvaro Sebastian, Aurélien Marabelle, cancer,
Objectives To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a,…
PURPOSEFinancial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with…
lving tools in select patients. The National Comprehensive Cancer Network (NCCN) guidelines define resectability criteria based on tumor involvement of the arteries and veins and…
Nature Cancer – Mellman and colleagues present a multiomic single-cell analysis of the effects of combined anti-TIGIT and anti-PD-1 blockade on T cell populations trafficking…
